



## Understanding the Potential of Host Defense Peptides in Treating Cancer

Guest Editors:

**Dr. Melanie R. Power Coombs**

Biology, Acadia University,  
Wolfville, Canada; and Pathology,  
Dalhousie University, Halifax, NS,  
Canada

[melanie.coombs@acadiau.ca](mailto:melanie.coombs@acadiau.ca)

**Dr. David W. Hoskin**

Departments of Pathology,  
Microbiology and Immunology,  
and Surgery, Dalhousie  
University, Halifax, NS, Canada

[d.w.hoskin@dal.ca](mailto:d.w.hoskin@dal.ca)

Deadline for manuscript  
submissions:

**30 June 2021**

### Message from the Guest Editors

Dear Colleagues,

Cancer is the second leading cause of death globally. The need is urgent to discover novel treatments for cancer that are curative and not associated with considerable toxicity. Identification of suitable drug targets is a major obstacle in cancer treatment strategies. Host defense peptides (HDPs) are biomolecules typically containing several cationic and hydrophobic amino acids that interact with the cell membrane, resulting in anti-microbial, anti-cancer, and immune modulatory activities. Anti-cancer peptides (ACPs) exhibit increased toxicity toward cancer cells compared to normal cells. The structure of ACPs impacts their mechanism of action, so better understanding ACPs will have clinical relevance.

It is my pleasure to invite you and your teams to contribute original research or review articles to this Special Issue. We are especially interested in articles that cover studies on the identification, roles, and molecular mechanisms of action of ACPs, and translational approaches to the use of ACPs of clinical relevance in cancer.





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Vladimir N. Uversky

Molecular Medicine, University of  
South Florida, Tampa, USA

## Message from the Editor-in-Chief

*Biomolecules* is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

## Author Benefits

**Open Access:**—free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** Indexed in the Science Citation Index Expanded (SCIE - Web of Science) and in **Scopus**. Citations available in MEDLINE (PubMed), full-text archived in PubMed Central.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2020).

## Contact Us

---

*Biomolecules*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomolecules](http://mdpi.com/journal/biomolecules)  
[biomolecules@mdpi.com](mailto:biomolecules@mdpi.com)  
[@Biomol\\_MDPI](https://twitter.com/Biomol_MDPI)